80 related articles for article (PubMed ID: 20435479)
1. Synthesis and evaluation of nitric oxide-releasing derivatives of farnesylthiosalicylic acid as anti-tumor agents.
Ling Y; Ye X; Ji H; Zhang Y; Lai Y; Peng S; Tian J
Bioorg Med Chem; 2010 May; 18(10):3448-56. PubMed ID: 20435479
[TBL] [Abstract][Full Text] [Related]
2. Novel nitric oxide-releasing derivatives of farnesylthiosalicylic acid: synthesis and evaluation of antihepatocellular carcinoma activity.
Ling Y; Ye X; Zhang Z; Zhang Y; Lai Y; Ji H; Peng S; Tian J
J Med Chem; 2011 May; 54(9):3251-9. PubMed ID: 21504204
[TBL] [Abstract][Full Text] [Related]
3. Farnesylthiosalicylic acid induces caspase activation and apoptosis in glioblastoma cells.
Amos S; Redpath GT; Polar G; McPheson R; Schiff D; Hussaini IM
Cell Death Differ; 2006 Apr; 13(4):642-51. PubMed ID: 16239932
[TBL] [Abstract][Full Text] [Related]
4. The Ras inhibitor farnesylthiosalicylic acid as a potential therapy for neurofibromatosis type 1.
Barkan B; Starinsky S; Friedman E; Stein R; Kloog Y
Clin Cancer Res; 2006 Sep; 12(18):5533-42. PubMed ID: 17000690
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and biological evaluation of furoxan-based nitric oxide-releasing derivatives of glycyrrhetinic acid as anti-hepatocellular carcinoma agents.
Lai Y; Shen L; Zhang Z; Liu W; Zhang Y; Ji H; Tian J
Bioorg Med Chem Lett; 2010 Nov; 20(22):6416-20. PubMed ID: 20932754
[TBL] [Abstract][Full Text] [Related]
6. The Ras inhibitor farnesylthiosalicylic acid (Salirasib) disrupts the spatiotemporal localization of active Ras: a potential treatment for cancer.
Rotblat B; Ehrlich M; Haklai R; Kloog Y
Methods Enzymol; 2008; 439():467-89. PubMed ID: 18374183
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological evaluation of novel farnesylthiosalicylic acid derivatives for cancer treatment.
Ling Y; Wang X; Zhu H; Wang Z; Xu C; Wang X; Chen L; Zhang W
Arch Pharm (Weinheim); 2014 May; 347(5):327-33. PubMed ID: 24435839
[TBL] [Abstract][Full Text] [Related]
8. Hybrid molecule from Farnesylthiosalicylic acid-diamine and phenylpropenoic acid as Ras-related signaling inhibitor with potent antitumor activities.
Ling Y; Wang Z; Wang X; Li X; Wang X; Zhang W; Dai H; Chen L; Zhang Y
Chem Biol Drug Des; 2015 Feb; 85(2):145-52. PubMed ID: 25043275
[TBL] [Abstract][Full Text] [Related]
9. Gene expression signature of human cancer cell lines treated with the ras inhibitor salirasib (S-farnesylthiosalicylic acid).
Blum R; Elkon R; Yaari S; Zundelevich A; Jacob-Hirsch J; Rechavi G; Shamir R; Kloog Y
Cancer Res; 2007 Apr; 67(7):3320-8. PubMed ID: 17409441
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological evaluation of farnesylthiosalicylamides as potential anti-tumor agents.
Ling Y; Wang Z; Zhu H; Wang X; Zhang W; Wang X; Chen L; Huang Z; Zhang Y
Bioorg Med Chem; 2014 Jan; 22(1):374-80. PubMed ID: 24300920
[TBL] [Abstract][Full Text] [Related]
11. Design and synthesis of furoxan-based nitric oxide-releasing glucocorticoid derivatives with potent anti-inflammatory activity and improved safety.
Fang L; Zhang Y; Lehmann J; Wang Y; Ji H; Ding D
Bioorg Med Chem Lett; 2007 Feb; 17(4):1062-6. PubMed ID: 17129724
[TBL] [Abstract][Full Text] [Related]
12. New derivatives of farnesylthiosalicylic acid (salirasib) for cancer treatment: farnesylthiosalicylamide inhibits tumor growth in nude mice models.
Goldberg L; Haklai R; Bauer V; Heiss A; Kloog Y
J Med Chem; 2009 Jan; 52(1):197-205. PubMed ID: 19072665
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of the Ras oncoprotein reduces proliferation of hepatocytes in vitro and in vivo in rats.
da Silva Morais A; Saliez A; Leclercq I; Horsmans Y; Stärkel P
Clin Sci (Lond); 2008 Jan; 114(1):73-83. PubMed ID: 17678500
[TBL] [Abstract][Full Text] [Related]
14. Getting at MYC through RAS.
Bachireddy P; Bendapudi PK; Felsher DW
Clin Cancer Res; 2005 Jun; 11(12):4278-81. PubMed ID: 15958607
[No Abstract] [Full Text] [Related]
15. Design, synthesis and anti-tumor evaluation of novel steroidal glycoconjugate with furoxan derivatives.
Li H; Wang K; Wan Q; Chen Y
Steroids; 2019 Jan; 141():81-95. PubMed ID: 30521816
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and anti-human hepatocellular carcinoma activity of new nitric oxide-releasing glycosyl derivatives of oleanolic acid.
Huang Z; Zhang Y; Zhao L; Jing Y; Lai Y; Zhang L; Guo Q; Yuan S; Zhang J; Chen L; Peng S; Tian J
Org Biomol Chem; 2010 Feb; 8(3):632-9. PubMed ID: 20090981
[TBL] [Abstract][Full Text] [Related]
17. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R
Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological evaluation of 3',4',5'-trimethoxychalcone analogues as inhibitors of nitric oxide production and tumor cell proliferation.
Rao YK; Fang SH; Tzeng YM
Bioorg Med Chem; 2009 Dec; 17(23):7909-14. PubMed ID: 19875299
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and anticancer activities of novel 3,5-disubstituted-1,2,4-oxadiazoles.
Kumar D; Patel G; Johnson EO; Shah K
Bioorg Med Chem Lett; 2009 May; 19(10):2739-41. PubMed ID: 19376704
[TBL] [Abstract][Full Text] [Related]
20. Ras inhibition increases the frequency and function of regulatory T cells and attenuates type-1 diabetes in non-obese diabetic mice.
Mor A; Kloog Y; Keren G; George J
Eur J Pharmacol; 2009 Aug; 616(1-3):301-5. PubMed ID: 19527709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]